ArticleInternational journal of bipolar disorders2026
Polycystic ovary syndrome in women with bipolar affective disorder or epilepsy exposed to valproic acid: a nationwide 16-year cohort study.
Article in International journal of bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth bipolar disorder (BD) and epilepsy (ES) have been linked to polycystic ovary syndrome (PCOS) that is one of the most common endocrine disorders in women of reproductive age. The antiseizures medication valproate is widely used in the treatment of both disorders but has been suspected to increase the risk of PCOS. Previous studies have been limited by small sample sizes and heterogeneous definitions. We aimed to investigate the association between valproate exposure and incident PCOS in females with BS and ES.
methodsWe conducted a register-based cohort study including all females in Denmark with a first diagnosis of BD (ICD-10: F30.x-F31.x) or ES (ICD-10: G40.x) between January 1, 2000, and July 31, 2022. Women with BD, ES, valproate exposure, or PCOS prior to January 1, 2000, were excluded. Exposure to valproate was primarily modeled as current cumulative exposure. We also included a never/ever analysis and an overall cumulative analysis, accumulating dosages over the entire study period. The outcome was incident PCOS (ICD-10: E28.2). Cox regression models adjusted for age at diagnosis and calendar year were applied.
resultsThe cohort comprised of 20,967 women, 8,003 diagnosed with BD and 12,964 diagnosed with ES. In total, 266 females developed PCOS during follow-up, of whom 160 had been exposed to valproate. In the main analysis, current cumulative exposure was strongly associated with PCOS, with HRRs rising from 4.43, 95%CI:3.42-5.73 (0-90 DDDs) to 7.08, 95%CI:3.85-13.03 (> 365 DDDs), P < 0.001. In the never/ever analysis, valproate exposure was also associated with increased PCOS risk (HRR 1.55, 95%CI:1.20-2.00). By contrast, overall cumulative exposure showed a less consistent pattern, with risk most clearly elevated in the highest dosage category (> 365 DDDs, HRR 2.04, 95%:CI 1.28-3.20), p < 0.01.
conclusionsValproate exposure was associated with an increased risk of PCOS. The risk was especially pronounced during current and cumulative exposure, whereas overall cumulative exposure suggested increased risk at higher thresholds. These findings suggest that PCOS risk may be driven by acute pharmacological effects, although long-term cumulative use may also contribute. The results reinforce recommendations to avoid valproate in women of reproductive age when possible.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.